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First Isolation of West Nile virus 
from a Patient with Encephalitis 
in the United States
Cinnia Huang,* Brett Slater,* Robert Rudd,* Nandakishore Parchuri,† Rene Hull,* 
Michelle Dupuis,* and Alexander Hindenburg†
West Nile virus (WNV) was isolated from a patient who developed encephalitis while undergoing treatment
with CHOP (cyclophosphamide, hydroxydoxorubicin, vincristine [Oncovin], predisone) and rituximab for a
non-Hodgkin B-cell lymphoma. Both standard reverse transcription–polymerase chain reaction (RT-PCR)
and Taqman RT-PCR established the diagnosis of WNV infection from cerebrospinal fluid (CSF). Several
whole blood samples and one serum sample underwent further testing. CSF and serum samples were
negative for WNV antibody; however, all samples were positive by both RT-PCR assays. Infectious virus
was recovered from a blood sample, and its identity was confirmed by using a WNV-specific immunofluo-
rescence assay. The complete WNV genomes determined from CSF and from the virus isolate adapted
from cell culture were the same. The results represent the first complete WNV genome sequence obtained
directly from human CSF and the first time that infectious WNV has been recovered from a patient with
encephalitis in North America.
est Nile virus (WNV), an arthropod-borne virus, is a
member of the Japanese encephalitis virus serocomplex
of the genus Flavivirus, family Flaviviridae (1), discovered in
Uganda in 1937 (2). Although WNV infections are usually
mild or asymptomatic, in some instances, a severe and fatal
encephalitis is produced, typically in the elderly (3). This virus
was first recognized in the Western Hemisphere in an outbreak
in New York in 1999 (4). As of October 2, 2002, a total of
2.671 cases of human illness in the United States have been
reported to the Centers for Disease Control and Prevention
(CDC). Although WNV has been recovered from mosquitoes,
birds, and horses, no isolations from humans have been
reported in the Western Hemisphere. Thus, all prior data
regarding the virus responsible for human illness in North
America have come from nucleic acid sequencing of the viral
genome in either cerebrospinal fluid (CSF) or brain tissue. We
describe the first isolation of WNV from a human case-patient
associated with the U.S. outbreak. Because the virus was also
directly detected by reverse transcription–polymerase chain
reaction (RT-PCR) in specimens from the same patient, we
were able to compare the entire genomic sequence of the
directly detected virus with that of the cell-culture isolate.
Case Report
The patient was a 70-year-old woman, who has been diag-
nosed with intermediate-grade, CD 20-positive, B-cell non-
Hodgkin lymphoma, involving a left intraparotid lymph node.
Staging workup demonstrated stage 1-A disease. Treatment
plans for the patient included three courses of CHOP (cyclo-
phosphamide, hydroxydoxorubicin, vincristine [Oncovin], and
predisone) chemotherapy plus rituximab (chimeric CD 20
monoclonal antibody), to be followed by involved field radia-
tion. After the first cycle of chemotherapy in July 2001, neu-
tropenia developed and the patient was treated with
granulocyte colony stimulating factor (GCSF) following both
the second and third cycles of chemotherapy. The third cycle
of chemotherapy was administered on September 11, 2001.
Four days later, she was treated with oral levofloxacin for low-
grade fever. On day 7 after chemotherapy, she was admitted to
the hospital with fever, cough, chills, rhinorrhea, joint aches,
decreased appetite, lethargy, and lightheadedness. She had no
recollection of any ill contacts or insect bites. She was a resi-
dent of southern Nassau County, New York, and did not have a
history of travel. Physical examination was within normal lim-
its. The patient was neutropenic; G-CSF was continued, and
she was given cefipime and gentamicin. One day after admis-
sion, she continued to have fever and experienced mild head-
aches that responded to acetaminophen. Urine cultures showed
penicillin-sensitive enterococci, and blood cultures were nega-
tive. Two days after admission, the patient continued to have
fever, headaches, and dizziness. A computed tomography (CT)
scan of the brain revealed no acute cerebral processes. On the
3rd day after admission, the patient was noted to be confused.
Further deterioration of mental status was noted, with incom-
prehensible speech, but she was able to follow commands.
Arterial blood-gas analysis showed an acute respiratory acido-
sis pattern, and the patient was subsequently intubated  and
transferred to the  intensive care unit. The patient had a
hypotensive episode secondary to atrial flutter, which required
cardioversion for stabilization. Ceftriaxone and ampicillin
were added to the antibiotic coverage, and antifungal treatment
was also initiated with lipid complex amphotericin B. After
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the patient’s hematologic parameters improved, G-CSF was
discontinued on day 9 of hospitalization, and the patient con-
tinued to be afebrile. Because of the clinical picture of enceph-
alitis and because the patient lived in an area where WNV was
endemic, lumbar puncture was performed on day 8, and a CSF
specimen was sent to the New York State Department of
Health laboratories for comprehensive PCR testing. Renal
tubular necrosis developed in the patient, leading to acute
renal failure by day 10, with further deterioration of her mental
status. Dialysis was initiated on day 16, and antibiotic therapy
was discontinued on day 17 as the patient remained afebrile
and the neutropenia resolved. The patient remained unrespon-
sive, staphylococcal septicemia developed, and she died on
day 35 of hospitalization. Autopsy showed a small focus of
perivascular lymphocyte cuffing in the mamillary bodies of
the brain, consistent with viral encephalitis. No evidence of
residual lymphoma was found.
Materials and Methods
The PCR Laboratory associated with the Virology Diagnos-
tic Services, Wadsworth Center, New York State Department of
Health, has developed a panel of PCR and RT-PCR assays that
allow tests on CSF and brain tissue for a wide range of viruses
associated with human central nervous system (CNS) infec-
tions. Specifically, the test battery includes herpes simplex
viruses (types 1 and 2), varicella-zoster virus, cytomegalovirus,
Epstein-Barr virus (Human herpesvirus 4), enteroviruses, and
the following arboviruses: Eastern equine encephalitis, Califor-
nia serogroup (LaCrosse virus [LACV], Jamestown Canyon,
and others), Powassan virus (POWV), St. Louis encephalitis
virus (SLEV), WNV, and Cache Valley virus.
RNA and DNA were simultaneously extracted from 0.25
mL of CSF sample with Trizol LS reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer’s instructions. Briefly,
RNA was first transcribed into cDNA with random primers
(Roche Diagnostics Corp., Indianapolis, IN), and an aliquot of
this cDNA (5 µL) was used in PCR reactions with primers for
detecting viruses in the test panel. Aliquots of DNA were also
examined for the presence of the herpesviruses in the panel.
Amplification products were analyzed on a 2% agarose (EM
Science, Gibbstown, NJ) gel containing ethidium bromide.
Routinely, for any virus for which a band corresponding to a
positive result is observed, the band is run into low melting
agarose, and sequenced directly on the gel slice without fur-
ther purification. DyeTerminator sequencing was performed
on an Applied Biosystems Model 373A automated sequencer
(Foster City, CA). For the TaqMan assay, one-step RT-PCR
Ready-Mix Kit (Applied Biosystems) was used. The primers
and probe for the quantification of the RNA copy number of
WNV used in this study are listed in Table 1.
Virus was isolated by using monolayers of Vero cells
grown in tubes. Aliquots of 0.01 and 0.05 mL of whole blood
were pretreated with antibiotics (penicillin and streptomycin)
for 30 min at room temperature (22°C); 1 mL of Eagle's mini-
mal essential medium containing 2% fetal bovine serum was
added to the treated blood samples, and the mixtures were
used to inoculate the Vero cell monolayers.
After incubation for 24 hr at 37°C, the monolayers were
rinsed with phosphate-buffered saline, 2 mL of fresh medium
was added, and the culture was subsequently monitored daily
for cytopathic effects (CPE). Cell monolayers that showed
CPE were harvested. To confirm that the infectious agent was
WNV, an aliquot of the supernatant serially diluted (10-4–10-6)
was used to infect fresh Vero cell monolayers. Virus-infected
monolayers from the second passage were examined for WNV
antigen by immunofluorescence assay (IFA) by using mono-
clonal antibody H5-46 (provided by CDC, Fort Collins, CO).
This monoclonal immunoglobulin (Ig) M antibody is specific
for a glycoprotein epitope on WNV.
Results
Diagnosis of WNV Infection
CSF was simultaneously examined for a panel of 11 viruses
by RT-PCR/PCR as described in Material and Methods. No
amplification product was observed for any other virus in the
PCR battery except WNV. Two primer pairs (CU9093/CL9279
and D87F/D156R) in the NS5 region (5,6) of the WNV genome
were used in the initial screening by standard RT-PCR (Table 1).
PCR products of appropriate size for both primer pairs were
obtained (Figure 1). RT-PCR was independently repeated on
another aliquot of CSF by using four primer pairs located in var-
 Table 1. Oligonucleotide primers and probe used in the standard RT-PCR and TaqMan assaysa
Primer Genome target Genome positionb Sequence (5′ –3′ ) RT-PCR product size (bp)
CU9093 NS5 9097–9120 AGYMGRGCHATHTGGTWYATGTGG 206
CL9279 NS5 9302–9283 TTCCAVCCDGCKGTRTCATC
D87F NS5 10034–10051 GCTCCGCTGTCCCTGTGA 70
D156R NS5 10103–10083 CACTCTCCTCCTGCATGGATG
Forward ENV 1160–1180 TCAGCGATCTCTCCACCAAAG 70
Reverse ENV 1229–1209 GGGTCAGCACGTTTGTCATTG
Probe ENV 1186–1207 TGCCCGACCATGGGAGAAGCTC
aRT-PCR, reverse transcription–polymerase chain reaction.
bGenome position according to GenBank accession no. AF196835.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1369
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ious genomic regions of WNV. PCR bands with the expected
sizes were present in all four reactions (data not shown). The
identity of the PCR bands was confirmed by sequence data
obtained directly from the PCR amplicon. The diagnosis of
WNV infection was based on the detection and sequence of the
WNV genome in CSF. Although the serologic test (IgM capture
enzyme-linked immunosorbent assay [ELISA]) on the CSF
sample was negative for WNV, according to the interpretations
set forth by CDC, the detection of viral genome sequence in
CSF meets the definition of a confirmed case. 
TaqMan Assays
To follow up this case, three whole-blood samples and one
serum sample were examined by both standard RT-PCR (prim-
ers in NS5 region) and TaqMan (primers in ENV region)
assays; the results are summarized in Table 2. The highest
RNA copy number, 2.5 x 106 copies/mL, was found in the
blood sample that was collected 3 days after the patient’s neu-
rologic symptoms appeared. WNV genome was also detected
in a serum sample collected on day 19 after onset of symp-
toms. Serologic tests (IgM capture ELISA and IgG ELISA) on
serum for Eastern equine encephalitis virus, LACV, POWV,
SLEV, and WNV were all negative.
Other Clinical Data
Laboratory studies of the CSF indicated the following val-
ues: leukocyte (WBC) count 8 mm3 with 66% neutrophils, 4%
lymphocytes, 4% atypical lymphocytes, and 26% monocytes;
erythrocyte count 0; glucose level 76 mg/dL; total protein
level 55 mg/dL, and lactate dehydrogenase level 35 IU/L. Fig-
ure 2 presents fever curve, WBC curve, and viremia data. The
serum immunoglobulins at the time of infection with WNV
were IgG 492 mg/dL (normal level [nl]) 700–1,500 mg/dL),
IgA 86 mg/dL (nl 65–450 mg/dL), and IgM 80 mg/dL (nl 45–
230 mg/dL).
Virus Isolation
The attempt to isolate WNV was carried out in a biosafety
level 3 laboratory not routinely used for arbovirus work and
located in a building separate from the facility where PCR test-
ing was conducted. This procedure had the dual advantage of
minimizing the possibility that any virus recovered originated
from a source other than the human specimen and also ensur-
ing that any isolate obtained would not lead to future spurious
PCR results. A blood sample collected on September 24, 2001,
and a CSF specimen collected on September 26, 2001, were
chosen for recovery of the virus because of the presence of
high-copy-number viral RNA. On day 6 postinfection, CPE
was observed in the tubes inoculated with 0.01 mL and 0.05
mL of blood, but not in the tube inoculated with 0.1 mL of
CSF. WNV was confirmed in the second-passage cell cultures
by IFA by using WNV-specific monoclonal antibody H5-46.
Figure 1. RT-PCR detection of West Nile virus RNA in cerebrospinal
fluid. Lanes 1 and 3: negative controls; lanes 2 and 4: cerebrospinal
fluid; lane M: 50-bp DNA ladder. Primer pairs used: lanes 1 and 2:
CU9093/CL9279; lanes 3 and 4: D87F/D156R.
Table 2. Detection of West Nile virus in human specimens by TaqMan and standard RT-PCR assaysa
Specimen Collection date RNA (copy/mL) CT Rn STD RT-PCR Serology Cell cultures
Blood 9/21/2001 2.2 x 103 31.6 0.48 Positive n.d. n.d.
Blood 9/24/2001 2.5 x 106 20.4 3.71 Positive n.d. Positive
CSF 9/26/2001 1.1 x 106 20.4 3.71 Positive Negative Negative
Blood 10/02/2001 5.4 x 104 25.8 2.70 Positive n.d. n.d.
Serum 10/10/2001 3.7 x 103 28.5 0.70 Positive Negative n.d.
aCT, threshold cycle number, the cycle number at which fluorescence increases above a fixed threshold value; Rn, normalized fluorescent signal, the fluorescent signal generated by the 
reporter dye; STD, standard; RT-PCR, reverse transcription–polymerase chain reaction; n.d.: not done, CSF, cerebrospinal fluid.RESEARCH
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Sequence Analysis
Since only a very small amount of CSF remained after the
diagnostic work-up, we carefully designed a protocol to gener-
ate PCR bands with sizes ranging from 500 to 1000 bp. This
protocol allowed the complete genome sequence of the virus
in the CSF to be determined by sequencing overlapping PCR
bands (GenBank accession no. AF533540). We used a similar
protocol to obtain the genome sequence of the isolate adapted
from cell culture and found that the sequence data from the
virus in the CSF and from the WNV isolate were identical. A
1648-bp fragment encoding the PreM, M, and part of the 5′ -E
gene was used for phylogenetic studies (Figure 3). The analy-
sis showed that the sequence data from this case are similar to
the sequence data obtained from human (7) (GenBank acces-
sion no. AF202541), horse (8) GenBank accession no.
AF260967), and bird (9) (GenBank accession no. AF196835)
WNV isolates in New York in 1999.
Discussion
This case is important for several reasons. It represents the
first instance in which WNV was recovered from a person in
the United States. It is also the first time that the entire
genomic sequence of WNV has been obtained from CSF from
a human case-patient. The sequence data from the virus
directly detected in the CSF and from the WNV isolate from
cell cultures are identical. Hindiyeh et al. (10) reported the iso-
lation of WNV from the blood of viremic patients who were
not immunocompromised and who seroconverted later. In con-
trast, the patient in this case was elderly and was undergoing
treatment for lymphoma. She was unable to mount an immune
response as shown by the fact that the results of serologic tests
on both CSF and serum specimens were negative.
To our knowledge, all previous attempts to recover WNV
from human patients associated with the North American out-
break have been unsuccessful. The ability to recover an infec-
tious isolate in this report may have been contingent on the
fact that the patient was immunologically impaired. She had
lymphoma and had been undergoing treatment with CHOP
plus rituximab for 2 months at the time the WNV infection
Figure 2. West Nile virus copy numbers in clinical samples and clinical.
WBC, leukocytes. Detailed sample information is listed in Table 2; day 1
is date the patient was hospitalized, 9/18/2001.
Figure 3. Phylogenetic relationships among West Nile virus strains.
Sequence data from the present case are shown in italics. The tree is
based on the 1,648-bp fragment encoding the preM, M, and part of the
5′ -E gene. Numbers at the nodes are bootstrap confidence estimates
based on 1,000 replicates.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1371
RESEARCH
developed. The relative role of immunosuppression caused by
the lymphoma itself compared with the immunosuppression
due to treatment of the lymphoma is unclear. At the time of the
WNV infection, the patient’s serum IgG levels were moder-
ately suppressed. This was most likely the result of lymphoma,
because a reduction in immunoglobulins, secondary to
impaired B-cell function from rituximab, usually occurs after
3 months of therapy (11). In a previous randomized study, eld-
erly patients receiving CHOP chemotherapy and rituximab
had increased their overall survival and had not experienced an
increase in toxic clinical effects compared with effects from
CHOP treatment alone (12). However, rituximab used as a sin-
gle agent has been reported to lead to excessive bacterial and
viral infections, including respiratory tract infections and her-
pes (13). Rituximab is also implicated as a risk factor for
unusual viral infections when used as an immunotherapy agent
in the peritransplant period of autologous stem cell transplant
in non-Hodgkin lymphoma patients (14). Another consider-
ation is the fact that the patient was neutropenic. The relation-
ship between neutrophil function and the severity of WNV
infection is unknown. The virus may be cleared by neutro-
phils, and the severity of the viral infection may have been due
to the fact that the patient was neutropenic at the time of the
acute infection. What lends credence to this hypothesis is the
observation that the highest viral titer as determined by PCR
coincided with the recovery of the WBC count. Following the
resolution of the myelosuppression, the RNA copy number of
the WNV in blood samples declined rapidly (from 1.1 x 106 to
5.4 x 104 copies/mL).
In summary, this report is the first of WN encephalopathy
in an immunocompromised patient undergoing treatment for
lymphoma. The patient’s serologic tests remained negative,
and the diagnosis was made by RT-PCR from both CSF and
peripheral blood, and by in vitro cultivation of the virus from
blood. WNV infection should therefore be considered in the
differential diagnosis of patients with lymphoma who exhibit
encephalopathy, even if serologic tests are negative for WNV.
Extra care should be taken to prevent patients with lymphoma,
especially those undergoing treatment, from being exposed to
WNV.
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